Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Pleural Effusion Size as Prognostic Marker in Patients With Malignant Pleural Effusion
Montero-Arias, Felicia , Cartin‐Ceba, Rodrigo , Rojas-Solano, José, Ugalde-Gamboa, Luis, Ramos-Esquivel, Allan

PLEURA | August 18, 2015 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1177/2373997515600657 Get It

Background: Inconsistent results have been reported regarding mortality predictors of malignant pleural effusion (MPE). Objective: We aim to describe prognostic features of MPE in patients evaluated over 5 years in a referral center. Methods: All consecutive MPEs (confirmed by pleural cytology or biopsy) from January 2009 to July 2014 were included in this retrospective cohort study. Clinical data were collected from medical registries. Overall survival (OS) rate was calculated with Kaplan-Meier method and compared by the log-rank test. Hazard ratios (HRs) were calculated by the Cox proportional regression model. Results: A total of 110 patients were identified. Mean OS was 8.3 months (range: 25-426 days). No difference in OS was noted based on tumor type. Patients with MPE <50% had a significant better survival than those with malignant pleural effusion ≥50% (median OS: 15.7 vs 5.7 months; HR: 1.71; 95% confidence interval [CI]: 1.06-2.78; P = .0026). After adjusting for confounding variables, MPE size was independently associated with mortality (HR: 1.78; 95% CI: 1.11-2.91; P < .001). No association between glucose or pH in pleural fluid and OS was noted. Conclusion: Our study showed that MPE size, as determined by chest X-ray, is significantly associated with mortality.
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer
Tice, Jeffrey A. , Miglioretti, Diana L. , Li, Chin-Shang, Vachon, Celine M. , Gard, Charlotte C. , Vachon, Celine M. , Kerlikowske, Karla , Miglioretti, Diana L

Journal of Clinical Oncology | August 17, 2015 | Volume: 33 | Issue: 28 | Pages: 3137-3143

10.1200/jco.2015.60.8869 | PMID 26282663 Get It

Purpose Women with proliferative breast lesions are candidates for primary prevention, but few risk models incorporate benign findings to assess breast cancer risk. We incorporated benign breast disease (BBD) diagnoses into the Breast Cancer Surveillance Consortium (BCSC) risk model, the only breast cancer risk assessment tool that uses breast density. Methods We developed and validated a competing-risk model using 2000 to 2010 SEER data for breast cancer incidence and 2010 vital statistics to adjust for the competing risk of death. We used Cox proportional hazards regression to estimate the relative hazards for age, race/ethnicity, family history of breast cancer, history of breast biopsy, BBD diagnoses, and breast density in the BCSC. Results We included 1,135,977 women age 35 to 74 years undergoing mammography with no history of breast cancer; 17% of the women had a prior breast biopsy. During a mean follow-up of 6.9 years, 17,908 women were diagnosed with invasive breast cancer. The BCSC BBD model slightly overpredicted risk (expected-to-observed ratio, 1.04; 95% CI, 1.03 to 1.06) and had modest discriminatory accuracy (area under the receiver operator characteristic curve, 0.665). Among women with proliferative findings, adding BBD to the model increased the proportion of women with an estimated 5-year risk of 3% or higher from 9.3% to 27.8% (P < .001). Conclusion The BCSC BBD model accurately estimates women's risk for breast cancer using breast density and BBD diagnoses. Greater numbers of high-risk women eligible for primary prevention after BBD diagnosis are identified using the BCSC BBD model.
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)
Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K., Beutler, Andreas S. , Ta, Lauren E., Lafky, Jacqueline M., Wagner‐Johnston, Nina D. , Ruddy, Kathryn J. , Dakhil, Shaker R. , Staff, Nathan P. , Loprinzi, Charles L. , Smith, Ellen M L, Wagner-Johnston, Nina D., Dakhil, Shaker, Lavoie Smith, Ellen M , Grothey, Axel , Staff, Nathan P

Journal of Clinical Oncology | August 17, 2015 | Volume: 33 | Issue: 30 | Pages: 3416-3422

10.1200/jco.2014.58.8533 | PMID 26282635 Get It

Purpose Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. Methods Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was assessed with use of the 20-item, European Organisation for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy. Results Three hundred eight (89%) of the 346 patients had at least one symptom of acute neuropathy with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic neurotoxicity, tingling was the most severe symptom, followed by numbness and then pain. During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. Patients with more severe acute neuropathy during the first cycle of therapy experienced more chronic sensory neurotoxicity (P < .0001). Conclusion Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies.
Taking the headache out of migraine
Borsook, David , Dodick, David W.

Neurology Clinical Practice | August 17, 2015 | Volume: 5 | Issue: 4 | Pages: 317-325

10.1212/cpj.0000000000000171 | PMID 26335578 Get It

First seizure management
Cascino, Gregory D. , Cole, Andrew J.

Neurology Clinical Practice | August 17, 2015 | Volume: 5 | Issue: 4 | Pages: 278-280

10.1212/cpj.0000000000000151 | PMID 26336628 Get It

DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients
Lorenzo‐Betancor, Oswaldo , Ogaki, Kotaro, Soto‐Ortolaza, Alexandra I., Walton, Ronald L., Strongosky, Audrey , Gerpen, Jay A. van, Uitti, Ryan J. , McLean, Pamela J. , Springer, Wolfdieter , Siuda, Joanna , Opala, Grzegorz, Krygowska‐Wajs, Anna , Barcikowska, Maria , McCarthy, A., Lynch, Timothy , Puschmann, Andreas , Rektorová, Irena , Sanotsky, Yanosh, Vilariño‐Güell, Carles , Farrer, Matthew J. , Ferman, Tanis J. , Petersen, Ronald C. , Parisi, Joseph E., Graff‐Radford, Neill R. , Ross, Owen A. , Soto‐Beasley, Alexandra I. , Labbé, Catherine , Siuda, Joanna S. , Czyźewski, K , Boeve, Bradley F. , Dickson, Dennis W. , Wszołek, Zbigniew K. , Ross, Owen A , Puschmann, Andreas , Springer, Wolfdieter , Ferman, Tanis J , Rektorova, Irena , Beasley, Alexandra I , McLean, Pamela J

European Journal of Neurology | August 17, 2015 | Volume: 22 | Issue: 9 | Pages: 1323-1325

10.1111/ene.12770 | PMID 26278106 Get It

BackgroundRecently, a novel mutation in exon 24 of DNAJC13 gene (p.Asn855Ser, rs387907571) has been reported to cause autosomal dominant Parkinson's disease (PD) in a multi‐incident Mennonite family.MethodsIn the present study the mutation containing exon of the DNAJC13 gene has been sequenced in a Caucasian series consisting of 1938 patients with clinical PD and 838 with pathologically diagnosed Lewy body disease (LBD).ResultsOur sequence analysis did not identify any coding variants in exon 24 of DNAJC13. Two previously described variants in intron 23 (rs200204728 and rs2369796) were observed.ConclusionOur results indicate that the region surrounding the DNAJC13 p.Asn855Ser substitution is highly conserved and mutations in this exon are not a common cause of PD or LBD among Caucasian populations.
Letter: acute cholangitis – understanding predictors of outcome
Kane, Sunanda V. , Tabibian, James H.

Alimentary Pharmacology & Therapeutics | August 17, 2015 | Volume: 42 | Issue: 6 | Pages: 777-777

10.1111/apt.13310 | PMID 26278563 Get It

Association between variants in inflammation and cancer‐associated genes and risk and survival of cholangiocarcinoma
Chaiteerakij, Roongruedee , Juran, Brian D., Aboelsoud, Mohammed M., Harmsen, William S. , Moser, Catherine D., Giama, Nasra H., Allotey, Loretta K., Mettler, Teresa A., Baichoo, Esha, Therneau, Terry M. , Roberts, Lewis R. , Lazaridis, Konstantinos N. , Chaiteerakij, Roongruedee , Zhang, Xiaodan , Roberts, Lewis R

Cancer Medicine | August 15, 2015 | Volume: 4 | Issue: 10 | Pages: 1599-1602

10.1002/cam4.501 | PMID 26276523 Get It

AbstractGenetic risk factors for cholangiocarcinoma (CCA) remain poorly understood. We assessed the effect of single‐nucleotide polymorphisms (SNPs) of genes modulating inflammation or carcinogenesis on CCA risk and survival. We conducted a case‐control, candidate gene association study of 370 CCA patients and 740 age‐, sex‐, and residential area‐matched healthy controls. Eighteen functional or putatively functional SNPs in nine genes were genotyped. The log‐additive genotype effects of SNPs on CCA risk and survival were determined using logistic regression and the log‐rank test, respectively. Initial analysis identified significant associations between SNP rs2143417 and rs689466 in cyclooxygenase 2 (COX‐2) and CCA risk, after adjusting for multiple comparisons (cutoff of P = 0.0028). However, these findings were not replicated in another independent cohort of 212 CCA cases and 424 matched controls. No significant association was found between any SNP and survival of CCA patients. Although COX‐2 has been shown to contribute to cholangiocarcinogenesis, the COX‐2 SNPs tested were not associated with risk of CCA. This study shows a lack of association between variants of genes related to inflammation and carcinogenesis and CCA risk and survival. Other factors than these genetic variants may play more important roles in CCA risk and survival.
Measures of satisfaction for providers and patients using same day teledermoscopy consultation
Kenney, Angela S., Yiannias, James A. , Raghu, T. S. , David, Paru S., Greig, Hope E, Chang, Yu‐Hui H., Chang, Yu‐Hui

International Journal of Dermatology | August 15, 2015 | Volume: 55 | Issue: 7 | Pages: 781-785

10.1111/ijd.12892 | PMID 26276548 Get It

AbstractBackgroundWe aimed to determine whether patients and providers were satisfied with teledermoscopy consultation for skin lesions.MethodsFrom 2010 to 2011, patients with clinically suspicious lesions were referred for teledermoscopy by internal medicine physicians. Lesions were digitally photographed using a dermatoscope accessory lens. Images were interpreted by an on‐call dermatologist. We conducted same day surveys of providers and patients after the evaluations.ResultsThe survey response rate was 100%. Of the 20 patients surveyed, all agreed that a teledermoscopic consult was convenient and helpful. Nineteen patients (95%) strongly agreed that teledermoscopy potentially was a cost‐saving tool. All providers thought the evaluations were helpful. Ninety‐five percent of providers and patients reported satisfaction with the ease of use of this technology.ConclusionsTeledermoscopy may give primary care providers the ability to consult with dermatologists when seeing patients in remote or medically underserved areas. This can streamline the referral process and decrease the number of referrals for benign lesions.